Champions Oncology Full Year 2025 Earnings: EPS: US$0.34 (vs US$0.54 loss in FY 2024)

Champions Oncology (NASDAQ:CSBR) Full Year 2025 Results

Key Financial Results

• Revenue: US$56.9m (up 14% from FY 2024).
• Net income: US$4.70m (up from US$7.28m loss in FY 2024).
• Profit margin: 8.3% (up from net loss in FY 2024). The move to profitability was primarily driven by higher revenue.
• EPS: US$0.34 (up from US$0.54 loss in FY 2024).

Trump has pledged to "unleash" American oil and gas and these 15 US stocks have developments that are poised to benefit.

All figures shown in the chart above are for the trailing 12 month (TTM) period

Champions Oncology Earnings Insights

In the last 12 months, the only revenue segment was Translational Oncology Solutions (TOS) contributing US$56.9m. The largest operating expense was General & Administrative costs, amounting to US$9.34m (39% of total expenses). Explore how CSBR's revenue and expenses shape its earnings.

Looking ahead, revenue is forecast to grow 8.3% p.a. on average during the next 3 years, compared to a 6.1% growth forecast for the Life Sciences industry in the US.

Performance of the American Life Sciences industry.

The company's shares are down 22% from a week ago.

Risk Analysis

You should learn about the 2 warning signs we've spotted with Champions Oncology.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.